These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35773445)

  • 41. Immunogenicity of SARS-CoV-2 vaccines in patients with cancer.
    Kakkassery H; Carpenter E; Patten PEM; Irshad S
    Trends Mol Med; 2022 Dec; 28(12):1082-1099. PubMed ID: 35999131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2.
    Ali F; Alom S; Shakya A; Ghosh SK; Singh UP; Bhat HR
    Arch Pharm (Weinheim); 2022 May; 355(5):e2100360. PubMed ID: 35244237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
    Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
    Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
    Roa CC; de Los Reyes MRA; Plennevaux E; Smolenov I; Hu B; Gao F; Ilagan H; Ambrosino D; Siber G; Clemens R; Han HH
    Hum Vaccin Immunother; 2024 Dec; 20(1):2301632. PubMed ID: 38206168
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine.
    van der Neut Kolfschoten M; Inganäs H; Perez-Peinado C; Calado da Silva Freire J; Melchers JM; van Dijk N; Przeradzka M; Kourkouta E; van Manen D; Vellinga J; Custers J; Bos R
    J Thromb Haemost; 2024 Apr; 22(4):1046-1055. PubMed ID: 38159648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
    Raiser F; Davis M; Adelglass J; Cai MR; Chau G; Cloney-Clark S; Eickhoff M; Kalkeri R; McKnight I; Plested J; Zhu M; Dunkle LM;
    Vaccine; 2023 Sep; 41(41):5965-5973. PubMed ID: 37652823
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers.
    Lounis M; Rais MA; Bencherit D; Aouissi HA; Oudjedi A; Klugarová J; Pokorná A; Klugar M; Riad A
    Front Public Health; 2022; 10():896343. PubMed ID: 35651866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.
    Le Gars M; Hendriks J; Sadoff J; Ryser M; Struyf F; Douoguih M; Schuitemaker H
    Immunol Rev; 2022 Sep; 310(1):47-60. PubMed ID: 35689434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines.
    Hwang J; Lee SB; Lee SW; Lee MH; Koyanagi A; Jacob L; Tizaoui K; Yon DK; Shin JI; Smith L
    J Autoimmun; 2021 Aug; 122():102681. PubMed ID: 34139631
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Establishment of human post-vaccination SARS-CoV-2 standard reference sera.
    Xiang J; Katz L; Winokur PL; Chaudhary A; Digmann B; Bradford R; Rashid S; Ghosh S; Robertson A; Menetski J; Xu M; Gao P; Chen CZ; Lee T; Poelaert B; Eastman RT; Hall MD; Stapleton JT
    J Immunol Methods; 2024 Jul; 530():113698. PubMed ID: 38823574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population.
    Theresa Pool SN; Shroff EH; Chetty A; Lewis L; Nonhlanhla YZ; Abdool Karim SS
    PLoS One; 2024; 19(4):e0299747. PubMed ID: 38578809
    [TBL] [Abstract][Full Text] [Related]  

  • 52. mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.
    Darling TL; Ying B; Whitener B; VanBlargan LA; Bricker TL; Liang CY; Joshi A; Bamunuarachchi G; Seehra K; Schmitz AJ; Halfmann PJ; Kawaoka Y; Elbashir SM; Edwards DK; Thackray LB; Diamond MS; Boon ACM
    Med; 2022 May; 3(5):309-324.e6. PubMed ID: 35584653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study.
    Fedele G; Trentini F; Schiavoni I; Abrignani S; Antonelli G; Baldo V; Baldovin T; Bandera A; Bonura F; Clerici P; De Paschale M; Fortunato F; Gori A; Grifantini R; Icardi G; Lazzarotto T; Lodi V; Mastroianni CM; Orsi A; Prato R; Restivo V; Carsetti R; Piano Mortari E; Leone P; Olivetta E; Fiore S; Di Martino A; Brusaferro S; Merler S; Palamara AT; Stefanelli P
    Front Immunol; 2022; 13():1021396. PubMed ID: 36389704
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines.
    Park H; Park MS; Seok JH; You J; Kim J; Kim J; Park MS
    J Microbiol; 2022 Mar; 60(3):308-320. PubMed ID: 35235179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines.
    Kaplonek P; Deng Y; Shih-Lu Lee J; Zar HJ; Zavadska D; Johnson M; Lauffenburger DA; Goldblatt D; Alter G
    Cell Rep Med; 2023 May; 4(5):101048. PubMed ID: 37182520
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
    Eliçabe RJ; Distel MN; Jofré BL; Leporati M; Silva JE; Arias JL; Gorlino CV; Funes SC; Velazquez M; Vitale P; Davicino RC; Di Genaro MS
    Vaccine; 2023 Jan; 41(2):476-485. PubMed ID: 36481109
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
    Turley CB; Tables L; Fuller T; Sanders LJ; Scott H; Moodley A; Woodward Davis A; Leav B; Miller J; Schoemaker K; Vandebosch A; Sadoff J; Woo W; Cho I; Dunkle LM; Li S; van der Laan L; Gilbert PB; Follmann D; Jaynes H; Kublin JG; Baden LR; Goepfert P; Kotloff K; Gay CL; Falsey AR; El Sahly HM; Sobieszczyk ME; Huang Y; Neuzil KM; Corey L; Grinsztejn B; Gray G; Rouphael N; Luedtke A;
    Vaccine; 2023 Jul; 41(33):4899-4906. PubMed ID: 37385888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of available COVID-19 vaccines in reducing deaths and perspective for next generation vaccines and therapies to counter emerging viral variants: an update.
    Wahid M; Jawed A; Mandal RK; Areeshi MY; El-Shall NA; Mohapatra RK; Tuli HS; Dhama K; Pellicano R; Fagoonee S; Haque S
    Minerva Med; 2023 Oct; 114(5):683-697. PubMed ID: 37293890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Course of 53 Previously Vaccinated Patients Admitted to the National Hospital in Warsaw, Poland with COVID-19 Between November 2021 and March 2022.
    Zaczyński A; Hampel M; Piątkiewicz P; Nasiłowski J; Butkiewicz S; Religioni U; Barańska A; Malm M; Neumann-Podczaska A; Vaillancourt R; Merks P
    Med Sci Monit; 2023 Apr; 29():e939841. PubMed ID: 37118889
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.